Navigation Links
US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
Date:8/16/2009

the US. Betaseron and Betaferon are registered trademarks of Bayer Schering Pharma AG.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "planned," "may," "committed," "long-term commitment," "will," "can," "likely," or similar expressions, or by express or implied discussions regarding potential future multiple sclerosis products or regarding potential future revenues from Extavia or other multiple sclerosis products. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any additional Novartis multiple sclerosis products will be approved for sale in any market. Nor can there be any guarantee that Extavia or such other products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of t
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
2. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
3. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
4. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
5. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
6. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
7. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
8. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
10. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
11. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2
... Patch Formulation May Provide New Option for Clinicians Concerned ... Systemic Exposure When ... Alpharma Inc. (NYSE: ALO ),a leading global ... presented this week at the American Pain Society annual,meeting ...
... Inc.,(Nasdaq: ARNA ) announced today that Taisho ... of a drug candidate under a GPCR-focused,partnership with ... drug candidate is a novel oral compound intended ... "We are very happy to see our long-standing ...
Cached Medicine Technology:Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 2Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd. 3
(Date:9/1/2014)... September 01, 2014 The B-cell non-Hodgkin’s ... across six major markets (the US, France, Italy, Germany, ... to $5.41 billion by 2018. , The competitive landscape ... Italy, Germany, Spain and the UK is poised to ... management of the four largest B-cell NHL indications, which ...
(Date:9/1/2014)... Barcelona, Spain Monday 1 September 2014: Daily fruit ... up to 40%, according to research presented at ESC ... The findings from the seven year follow-up study of ... found that the more fruit people ate, the more ... "CVD, including ischaemic heart disease (IHD) and stroke, is ...
(Date:9/1/2014)... As well as having completed the ... pursuing counselor certification in Louisiana. , "I ... training program as well as the Counselor training ... personally and professionally. I am not only dedicated ... to do so. As a Non Violent Crisis ...
(Date:9/1/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... TECHNOLOGIES AND GLOBAL MARKETS , the global market for ... and is expected to reach $38.7 million in 2014. ... by 2019, which is equivalent to 64.9% compound annual ... transport (RMT) segment is forecasted to grow at a ...
(Date:9/1/2014)... Oakdale, MN (PRWEB) September 01, 2014 In honor ... place on Aug. 22, Animal Emergency & Referral Center of Minnesota ... veterinarian visits a priority for their cats. , Many people don’t ... “it’s too much of a hassle,” but they wouldn’t decide not ... no signs of a cavity. The same goes for pets. Just ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... GAITHERSBURG, Md., Dec. 5 Panacea Pharmaceuticals, ... a fully human sequence,monoclonal antibody against HAAH ... in collaboration with the Massachusetts Institute of ... efficacy in animal,models of cancer. Having a ...
... publication Head and Neck Pathology. Published under the Humana ... North American Society for Head and Neck Pathology (NASHNP). ... December 2007, it will be available free of charge for ... Pathology will present scholarly papers, reviews and case reports that ...
... new ways of tweaking the molecular structure of antibiotics ... fight against powerful super bugs. , The work, led ... geneticist Professor Colin Smith, is published online today (Wednesday ... of the Journal of the American Chemical Society. , ...
... Clinical study compares rotational stability of two differently designed, ... of every day viewing conditions, JACKSONVILLE, Fla., Dec. ... vision may sometimes fluctuate during the day, the answer,may ... new clinical study,demonstrates. The findings, say researchers, may be ...
... Inc., a,medical device company developing endovascular devices for ... announced,the appointment of Christopher R. Barys to the ... to FlowCardia with over 16 years of,experience in ... in the,interventional endovascular products field., Most recently, ...
... Alliance, the leading,management consulting firm specializing in the ... Vice President,of the firm,s Business Development practice, will ... at the Strategic Research,Institute,s (SRI) Pharma & Biotech ... on December 10-11, 2007, at the San Diego ...
Cached Medicine News:Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 2Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 3Health News:Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product 4Health News:Scientists strike blow in superbugs struggle 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 2Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 3Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 4Health News:Contact Lens Shift Can Compromise Vision of People with Astigmatism with the Blink of an Eye 5Health News:FlowCardia, Inc. Appoints Chris Barys Senior VP, Sales 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 2Health News:Campbell Alliance Business Development Practice Leader to Co-Chair and Keynote at SRI Pharma Licensing Summit 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: